期刊文献+

血管内皮生长因子、基质金属蛋白酶-2、-9在舌鳞状细胞癌组织中的表达及其临床意义 被引量:3

The expression and clinical significance of MMP-2 、MMP-9 and VEGF in tongue squamous cell carcinoma
原文传递
导出
摘要 目的探讨血管内皮生长因子(VEGF)、基质金属蛋白酶-2(MMP-2)及基质金属蛋白酶-9(MMP-9)在舌鳞状细胞癌组织中的表达及其临床意义。方法采用免疫组织化学sP法检测60例舌鳞状细胞癌及20例正常舌组织手术切除标本中VEGF、MMP4与MMPO的表达。结果舌鳞状细胞癌组织中VEGF、MMP4与MMPO的表达明显高于正常舌组织(均P〈0.05),Ⅲ+Ⅳ期和有淋巴结转移的患者又明显高于Ⅰ+Ⅱ期和无淋巴结转移的患者(均P〈0.05)。舌鳞状细胞癌VEGF和MMP-2与MMPO的表达呈正相关(r=0.489、0.512,P〈0.05)。结论VEGF、MMP-2与MMPO在舌鳞状细胞癌中的表达与淋巴结转移、TNM分期密切相关,VEGF、MMP4与MMPO在舌鳞状细胞癌生长、侵袭和转移过程中可能起着重要的作用,并具有协同作用。 Objective To investigate the expression of vascular endothelial growth factor (VEGF), matrix metalloproteinase-2(MMP-2) and matrix metalloproteinase-9 (MMP-9) in tongue squamous cell carcinoma and the clinical significance. Methods The expression of MMP-2, MMP-9 and VEGF in 60 cases of tongues quamous cell carcinoma tissues and in 20 cases of normal tongues tissues were examined by immunochemistry. Results The expression of MMP-2, MMP-9 and VEGF was higher in tongues quamous cell carcinoma than that in normal pancreatic parenchyma. In cases with lymph nodes metastasis and TNM stage Ⅲ+Ⅳ, the expression of two markers were significantly higher than those without lymph nodes metastasis and TNM stage Ⅰ+Ⅱ (P 〈 0.05). A positive correlation was found between the expression of VEGF and MMP-2, MMP-9 in tongues quamous cell carcinoma ( P 〈 0. 05 ). Conclusion The expression of MMP-2, MMP-9 and VEGF was closely correlated with lymph nodes metastasis and TNM stage of tongues quamous cell carcinoma(P 〈0.05). VEGF and MMP-2, MMP-9 play an important role in the development of tongues quamous cell carcinoma, may cooperate with each other.
出处 《中国基层医药》 CAS 2012年第3期362-364,共3页 Chinese Journal of Primary Medicine and Pharmacy
关键词 鳞状细胞 血管内皮生长因子 基质金属蛋白酶-2 基质金属蛋白酶-9 Tongue Carcinoma, squamous cell vascular endothelial growth factor matrix metallop roteinase-2 matrix metalloproteinase-9
  • 相关文献

参考文献9

二级参考文献58

  • 1郭连瑞 徐文怀.血管内皮生长因子和基质金属蛋白酶-9与大肠癌演进过程的相关性研究[J].实用癌症杂志,2000,14(4):35-39.
  • 2David W Leung, George Cachianes, Wun-Jing Kuang, et al. Vascular endothelial growth factor is a secreted angiogenicmitogen. Science,1989,246(4935):1306-1310.
  • 3Brekken RA, Thorpe PE . Vascular endothelial growth factor and vascular targeting of solid tumors. Anticancer Res,2001,21(6B) :4221-4229.
  • 4Jia HY, Jezequal S,Lohr M. Peptides Encoded by Exon6 of VEGF inhibit Endothelial cell Biological response and Angiogenesis induced by VEGF. Biochem Biophy Res Commun, 2001,283(1):164-173.
  • 5Bates DO, Heald RI, Curry FE,et al. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol, 2001,533(Pt1):263-272.
  • 6Maxwell PH. Activation of the HIF pathway in cancer.Curr Opin Genet Dev,2001,11(5):293-299.
  • 7Bruce I Terman, Konstantin V Stoletov. VEGF and tumor angiogenesis. J Biol and Med,2001,18(2):59-66.
  • 8Cox G, Jones JL, Walker RA, et al. Angiogenesis and non-small cell lung cancer. Lung cancer, 2000,27 (2): 81-100.
  • 9Baillie R, Harada K, Bradley NJ, et al. Expression of vascular endothelial growth factor in normal and tumor oral tissues with different antibodies. The Histochemical Journal, 2001,33(2):287-294.
  • 10Maehara Y, Kabashima A, Koga T,et al. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery, 2000,128(3) :408-416.

共引文献57

同被引文献34

  • 1侯振江,张宗英.血管内皮生长因子及其受体检测在恶性肿瘤诊疗中的应用[J].诊断学理论与实践,2005,4(1):86-88. 被引量:18
  • 2Limpaiboon T, Sripa B, Wongkham S, et al. Anti-p53 antibodies and p53 protein expression in eholangiocareinoma [ J ]. Hepatogastroenterology ,2004,51 (55) :25-28.
  • 3Bongiovanni L, Pirozzi F, Guidi F, et al. Bradeion ( SEPT4 ) as aurinary marker of transitional cell bladder cancer: a real-time pol- ymerase chain reaction study of gene expression. J Uro1,2012,187 (6) :2223-2227.
  • 4Protzel C, Ruppin S, Kakies C, et al. 168 Genetic alterations of the KEAP1/NRF2 pathway in transitional cell carcinomas of the bladder. Eur Urol Supp1,2012,11 ( 1 ) : 168-173.
  • 5Beleik JT, Qi Y, Kaufmann BA, et al. Cardiovascular and systemic mierovaseular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coil Cardio1,2012,60 (7) :618-625.
  • 6Stollman TH, Scheer MG, Leenders WP. Specific imaging of VEGF- A expression with radiolabeled anti-VEGF monoclonal antibody. Int J Cancer,2008,122 (7) :2310-2314.
  • 7Li Z, Qi F, Qi L, et al. VEGF-C as a decision-making biomarker for selected patients with invasive bladder cancer who underwent bladder-preserving radical surgery. Arch Med Res, 2011,42 ( 5 ) : 405-411.
  • 8Vahola R, Salven P, Heikkila P. VEGFR-3 and its ligand VEGF- C are associated with angiogenesis in breast cancer. Am J Pathol, 1999,154(5) :1381.
  • 9Saaristo A, Partanen TA, Arola J, et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in the nasal mucosa and in nasopharyngeal tumors. Am J Pathol,2000,157(1) :7-14.
  • 10Suzuki K, Morita T, Tokue A. Vascular endothelial growth factor- C) VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int J Urol, 2005,12 ( 2 ) : 152.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部